Anika Therapeutics (ANIK) Tops Q4 EPS by 45c ;Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.40 --0%
Revenue Growth %: +5.9%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
KTB, CABO, FDUS, More
Revenue Growth %: +5.9%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.31, $0.45 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.1 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $116.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
- NewLake Capital Partners, Inc. (NLCP) Misses Q2 EPS by 9c
- CompX International (CIX) Reports Q3 EPS of $0.44
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
